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ABSTRACT
Radiotherapy with breast-conserving therapy plays a crucial role in the treatment of early breast cancer.
However, optimal radiotherapy targets have been controversial. We therefore evaluated regional recurrence in
breast cancer patients with one to three positive lymph nodes (LNs) treated with breast-conserving surgery
(BCS) followed by whole-breast irradiation (WBI). From 1993 to 2010, 121 breast cancer patients with one to
three positive LNs who underwent BCS followed by WBI were analyzed. All patients underwent radiotherapy
with two tangential ﬁelds to the whole breast. To evaluate the radiation dose to the axillary LNs, we contoured
axillary LNs area and evaluated the dose–volumetric parameters. The median follow-up time was 112.4 months
(range, 15.6–248.1 months). The 5-year overall survival and disease-free survival rates were 95.6% and 86.6%,
respectively. The 5-year regional recurrence–free rate (RRFR) was 97.4%. During follow-up, six patients had
regional recurrence. The pathological T stage was the factor best associated with the 5-year RRFR using the log-
rank test, with 100.0% in the pT1 cohort versus 94.7% in the pT2–4 cohort (P < 0.01). The radiation dose to
the axillary LNs did not contribute to the RRFR. In conclusion, while the pathological T stage was the prognos-
tic factor best associated with regional recurrence, few regional recurrences were observed in early breast cancer
patients with one to three LNs treated with BCS followed by WBI. Unintentional radiation doses to the axillary
LNs using standard WBI were not related to the RRFR after axillary dissection.
KEYWORDS: radiotherapy, breast cancer, breast-conserving therapy
INTRODUCTION
Breast-conserving therapy (BCT) has been the standard treatment
option for women with early breast cancer. Radiotherapy after
breast-conserving surgery (BCS) plays a fundamental role in local
control, and Fisher et al. [1] reported that BCS plus radiotherapy
reduced the risk of local recurrence. The results of a meta-analysis
performed by the Early Breast Cancer Trialists’ Collaborative
Group (EBCTCG) showed the need for radiotherapy after BCS
[2]. While adjuvant radiotherapy plays a crucial role in the treat-
ment of early breast cancer, optimal radiotherapy targets remain
controversial.
The results of the EBCTCG meta-analysis showed that radio-
therapy involving the chest wall and regional lymph node (LN)
areas reduced recurrence and breast cancer mortality in women
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with positive LNs after mastectomy and axillary dissection [3].
When women with one to three, and four or more involved axillary
LNs were considered separately, the beneﬁcial effects of postmas-
tectomy radiotherapy were evident in each group. In general,
patients with positive LNs have a higher risk of axillary node recur-
rence after BCT than do those with negative LNs [4, 5]. To
improve regional control, regional node irradiation (RNI) is
required for patients with more than four positive LNs. However,
the role of RNI after BCS in patients with early breast cancer with
one to three positive axillary LNs remains controversial. In the
MA.20 trial, Whelan et al. [6] reported that the addition of RNI,
including irradiation of the internal mammary, supraclavicular and
axillary LNs, to whole breast irradiation (WBI) reduced the locore-
gional and distant metastasis–free survival rates in breast cancer
patients treated with BCT. The majority of patients in the MA.20
trial had one to three positive nodes. Poortmans et al. [7] reported
in the EORTC 22922–10925 trial that internal mammary and med-
ial supraclavicular LN irradiation together with WBI or chest wall
irradiation improved the disease-free survival (DFS) and distant
DFS rates. However, neither of these trials showed a signiﬁcant
beneﬁt in the primary endpoint of overall survival (OS). Although
the National Comprehensive Cancer Network (NCCN) guideline
states that irradiation to the infraclavicular and supraclavicular areas
should be strongly considered for patients with one to three positive
axillary LNs [8], several other studies reported a low recurrence rate
in pathological N1 breast cancers, even without RNI [5, 9, 10].
Axillary LNs are sometimes unintentionally irradiated by WBI
using standard tangential ﬁeld techniques; however, some research-
ers reported that the dose delivered to the axillary nodes was not a
sufﬁcient therapeutic dose [11, 12]. Whether an adequate radiation
dose to the axillary nodes affects the prognosis for breast cancer
remains unclear. No studies have reported the relationship between
the axillary node dose and regional recurrence. In the following
retrospective cohort study, we therefore evaluated the outcomes of
BCT including postoperative WBI without RNI for breast cancer
patients with one to three positive LNs and assessed prognostic fac-
tors for regional recurrence. Furthermore, we evaluated the radiation
dose to the axillary LNs using WBI and investigated the possible
relationship between the radiation dose and regional recurrence.
MATERIALS AND METHODS
Patients
From 1993 to 2010, 620 patients who underwent BCT were histo-
logically diagnosed with breast cancer at our institution. Of these,
389 patients had negative LN metastasis, 133 patients had one to
three positive axillary LNs, 35 patients had four or more positive
LNs, and the status of LN metastasis was unknown in 63 patients.
In this study, we excluded three patients whose follow-ups were
interrupted within a year after BCS, and nine patients who under-
went irradiation of the supraclavicular and/or parasternal LN areas,
from 133 patients with one to three positive LNs. Although there
were no deﬁnite criteria for supraclavicular radiotherapy (SCRT)
and/or parasternal radiotherapy (PSRT) during this period in our
institution, younger patients or patients with a higher percentage of
positive nodes to dissected nodes were likely to receive SCRT
and/or PSRT. We did not exclude patients who died or who
developed recurrence within a year after BCS. Thus, we analyzed a
total of 121 patients. This study was approved by the institutional
review board of our institution.
Treatment
All patients underwent BCS with axillary LN dissection or sentinel
LN biopsy followed by WBI. Axillary LN dissection was performed
on 113 patients (93.3%), and the remaining 8 patients (6.7%)
received sentinel LN biopsy without further LN dissection. Fifty-
nine patients (52.2%) underwent Level 1 axillary dissection, 21 patients
(18.6%) underwent Level 2 dissection, and 9 patients (8.0%) under-
went Level 3 dissection. The details of the axillary treatment of the
remaining 24 patients (21.2%) were unknown. Radiotherapy was
performed using a 60Cobalt or 4- or 6-MV photon beam from a lin-
ear accelerator. A tangential technique with a rectangular ﬁeld was
used. The cranial border of the treatment ﬁeld was at the sternal
notch, and the caudal border was at 1 cm below the inframammary
fold. WBI was performed daily using a dose of 50 Gy in 25 fractions
in 117 patients, a dose of 42.56 Gy in 16 fractions in 1 patient, and a
dose of 42.4 Gy in 16 fractions in 3 patients. In the case of a positive
or close primary surgical margin, WBI was followed by an additional
boost to the tumor bed with a dose of 10.0 Gy in 5 fractions or
10.6 Gy in 4 fractions. The axillary LN regions were not irradiated
intentionally. Systemic chemotherapy was given to 61 patients
(50.4%). Thirty-one of 61 patients (50.8%) received oral pyrimidine
ﬂuoride agents such as doxiﬂuridine, tegafur/uracil, or capecitabine.
Thirteen patients (21.3%) received anthracycline-based regimens,
11 patients (18.0%) received a sequence of anthracyclines and tax-
anes, two patients (3.3%) received taxanes alone, and another regi-
men was used in four patients (6.6%). Hormone therapy was given
to 81 patients (66.9%).
Radiation dose to axillary LNs
To evaluate the radiation dose to the axillary LNs, we contoured
three LN areas involving axillary Level 1 LNs, the interpectoral
LNs, and axillary Level 2 in accordance with the European Society
for Radiotherapy & Oncology (ESTRO) consensus guidelines on
target volume delineations [13]. We did not contour axillary Level 3
because this level was not usually included in the ﬁeld of standard
tangential WBI. Computed tomography images for planning of 3D
radiotherapy from 96 patients were available. All treatment plans
were reproduced using the Eclipse Treatment Planning System
version 8.6 (Varian Medical Systems) from the information includ-
ing isocenter coordinates, ﬁeld sizes, gantry and collimator angles,
and monitor unit. The dose calculation algorithm used for planning
was the pencil beam convolution algorithm. Treatment plans with
hypofractionation were converted to standard 2 Gy equivalent dose
fractions using a linear–quadratic model with alpha/beta ratio of
4 Gy. The dose–volumetric data were analyzed for the mean dose
and the percentages of volumes irradiated at >45 Gy (V45Gy) and
>40 Gy (V40Gy) for each LN area.
Statistical analysis
We deﬁned regional recurrence as any tumor recurrence in the ipsi-
lateral axilla, supraclavicular, or internal mammary areas. Ipsilateral
breast tumor recurrence was deﬁned as a failure in the ipsilateral
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breast. The regional recurrence–free rate (RRFR) was calculated
from the date of the ﬁrst BCS to the date of the event. All
recurrences were diagnosed by either a clinical or radiological exam-
ination. OS was calculated from the date of the BCS to the date of
death of any cause or the date of the last follow-up. DFS was calcu-
lated from the date of the ﬁrst BCS to the date of any ﬁrst
recurrence, the development of another cancer, or death from any
cause. Survival estimates were calculated using the Kaplan–Meier
method. Survival rates were compared using the log-rank test
between two groups. All statistical tests and P-values were two-
tailed, and P-values of <0.05 were considered signiﬁcant.
RESULTS
Patient characteristics
The characteristics of the patients in the study cohort are shown in
Table 1. The median age at diagnosis was 52 years (range, 26–
78 years). Of these patients, 61 (50.4%) and 60 (49.6%) were diag-
nosed with pT1 and pT2–4 tumors, respectively. Eighty-three
patients (68.6%) had only one positive LN, and 38 patients
(31.4%) had two or three positive LNs. The percentage of patients
who were estrogen receptor–positive was 74.4% (n = 90). The
median number of removed LNs was 13 (range, 2–60), and the
median percentage of positive LNs was 10% (range, 2%–50%).
OS, DFS and pattern of recurrence
The median follow-up time was 112.4 months (range, 15.6–248.1
months) for all patients. The OS and DFS rates were 95.6% and
86.6% at 5 years and 92.9% and 70.8% at 10 years, respectively. The
Kaplan–Meier curves for OS and DFS are shown in Fig. 1a and b.
One patient developed contralateral breast cancer, and one patient
developed another type of cancer. During follow-up, 35 recurrences
in 30 patients developed in 7 ipsilateral breasts, 5 supraclavicular
LNs, 1 axillary LN, and 22 distant sites, respectively. Table 2 lists
the sites of the ﬁrst recurrence. Two patients had regional LN recur-
rences only.
Regional recurrence
The 5- and 10-year RRFRs were 97.4% and 93.7%, respectively.
During follow-up, six patients (5.0%) developed regional recurrence.
One patient had two recurrences in the interpectoral LNs and in
axillary Level 3, while ﬁve patients had a recurrence in the supracla-
vicular area. Using univariate analysis, the most signiﬁcant factor
associated with the RRFR was the pathological T stage, with a
5-year RRFR of 100.0% in pT1 tumors versus 94.7% in pT2–4
tumors (P< 0.01). All of the recurrences occurred in pT2 patients.
The Kaplan–Meier curve analysis for the RRFR according to patho-
logical T stage is shown in Fig. 2. No signiﬁcant differences were
observed for age (P = 0.30), histological grade (P = 0.54), lympho-
vascular invasion (P = 0.10), hormonal receptor status (P = 0.76),
number of positive LNs (P = 0.07), percentage of positive LNs
(P = 0.94) or using systemic chemotherapy (P = 0.10). There were
very few recurrences; thus, the aforementioned factors using multi-
variate analysis could not be analyzed.



































Median number of dissected LNs 13 (2–60)
Median percentage of positive LNs 10% (2–50)
LNs = lymph nodes.
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Radiation dose to axillary LNs
Figure 3 shows the radiation ﬁeld of the tangential technique and
axillary radiation dose coverage for a representative case. The dose–
volume parameters for axillary Level 1, the interpectoral LNs, and
Level 2 of 96 patients are shown in Table 3. The averaged mean
dose to Level 1, the interpectoral LNs, and Level 2 were 35.4 ± 6.6,
30.8 ± 10.1 and 10.1 ± 7.8 Gy, respectively. From these data, the
dose irradiated to the Level 2 area was negligible; thus, we con-
ducted further studies using Level 1 and the interpectoral LNs.
Table 4 shows the relationship between the average mean dose
to the axillary LNs and the RRFR divided into two groups accord-
ing to the percentage of positive LNs. Truong et al. [14] reported
that ≥20% positive LNs was associated with locoregional failure.
Based upon this report, we set the cut-off value at 20%. However,
the radiation doses to axillary Level 1 and the interpectoral LNs
were not beneﬁcial for the RRFR in patients with <20% or ≥20%
positive LNs. The numbers of patients with <20% and ≥20%
positive LNs were 77 and 19, respectively. Neither the dose to
Level 1 nor to the interpectoral LNs were related to the RRFR in
patients with either a higher or lower percentage of positive LNs.
DISCUSSION
Two randomized trials have demonstrated that RNI added to WBI
improves DFS in patients with early-stage breast cancer. However,
only 43% had one to three positive LNs in the EORTC22922/
10925 trial. Therefore, the efﬁcacy of RNI for patients with one to
three positive LNs remains controversial. Several retrospective ana-
lyses have reported results of SCRT for such patients. Fortin et al.
[9] reported that the regional control rate was 93.0% for WBI, but
signiﬁcantly higher (98.0%) for WBI and SCRT. However, Grills
Fig. 1 . Kaplan–Meier curves for (a) overall survival and (b) disease-free survival of all patients. OS = overall survival,
DFS = disease-free survival.
Table 2. Site of ﬁrst recurrence
n (%)
Distant organ 20 (66.7)
Ipsilateral breast 5 (16.7)
SC + distant organ 2 (6.7)
SC + ipsilateral breast 1 (3.3)
SC 1 (3.3)
Ax 1 (3.3)
Overall site 30 (100)
SC = supraclavicular node, Ax = axillary node.
Fig. 2. Kaplan–Meier curves for regional recurrence–free
rate according to pathological T stage of all patients.
RRFR = regional recurrence–free rate.
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et al. [5] reported that 6 (3.2%) of 188 patients who received WBI
without SCRT developed regional node failure, and SCRT did not
affect the rate of axillary or supraclavicular failure in patients with
one to three positive LNs. Several other reports showed a low recur-
rence rate in regional LN areas for patients with one to three posi-
tive LNs when treated with BCS followed by WBI. Bedi et al. [15]
reported that 4 of 202 patients (2%) developed recurrence in the
ipsilateral supraclavicular LNs and that 4 (2%) developed recurrence
in the ipsilateral axillary and/or internal mammary LNs. Truong
et al. [14] also reported a low incidence of regional recurrence of
5.4% (68 of 1255 patients). In our study, 6 patients (5%) treated
with WBI alone developed regional recurrence, with a 5-year RRFR
of 97.4% (similar to other studies). Moreover, only 2 patients
(1.7%) developed their ﬁrst recurrence in the regional area alone.
Taken together, the results from our study indicate that the rate of
regional recurrence of WBI alone is substantially low and that the
absolute gains of SCRT may be negligible.
Nine patients who underwent SCRT and/or PSRT were
excluded in this study. Although no deﬁnite criteria existed for
SCRT and/or PSRT, these patients might be considered to have
had higher risk for regional recurrence, such as younger age, or a
higher percentage of positive nodes. Thus, there is a possibility that
the RRFR might have been lower if the patients with SCRT and/or
PSRT had been included in the analysis.
RNI may increase the risk of treatment complications such as
lymphedema and pneumonitis. Powell et al. [10] reported that
the 10-year risk of developing these complications was 1.8% for
WBI alone versus 8.9% for WBI and SCRT after BCS for the treat-
ment of early-stage breast cancer. Kahán et al. [16] reported that
irradiation of the axillary and supraclavicular LNs favored the devel-
opment of pneumonitis. The MA.20 trial also showed that patients
in the RNI group had higher rates of Grade ≥2 lymphedema (8.4%
and 4.5%, respectively; P < 0.01) and pneumonitis (1.2% and 0.2%,
respectively; P = 0.01) [6]. Based on these observations, the adapta-
tion of SCRT should be considered carefully.
Viani et al. [17] reported that the factors associated with supra-
clavicular recurrence free survival (SCRFS) were the number of
positive axillary LNs, hormone receptor status, T stage, lymphovas-
cular invasion, nuclear grade, and extracapsular extension for
patients with N1 breast cancer treated by BCS with axillary LN dis-
section or sentinel biopsy followed by WBI. Similarly, Yu et al. [18]
suggested that lymphovascular invasion and the number of involved
axillary LNs had a signiﬁcant effect on supraclavicular recurrence of
pathological N1 tumors in breast cancer patients treated with mast-
ectomy or BCT. They also reported that the highest level of involved
axillary LNs, the percentage of positive LNs, and extracapsular
extension showed signiﬁcant effects on SCRFS. Both reports
showed that the number of prognostic factors was signiﬁcantly
Fig. 3. Digitally reconstructed radiograph of tangential ﬁelds (left) and axillary radiation dose coverage in a representative
case (right).
Table 3. Dose–volume parameters for axillary nodes
Level 1 Interpectoral nodes Level 2
Mean dose (Gy) 35.4 ± 6.6 30.8 ± 10.1 10.1 ± 7.8
V40 Gy (%) 51.0 ± 25.2 34.7 ± 35.6 3.0 ± 9.8
V45 Gy (%) 31.7 ± 28.2 17.9 ± 27.0 0.6 ± 2.9
V40 Gy = percentage of volume receiving >40 Gy, V45 Gy = percentage of volume
receiving >45 Gy.















≥35 Gy <35 Gy ≥35 Gy <35 Gy
% of positive LNs
<20% 92.9% 92.9% 0.52 88.9% 93.6% 0.72
≥20% 100.0% 75.0% 0.11 87.5% 100.0% 0.39
RRFR = regional recurrence–free rate, LNs = lymph nodes.
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correlated with supraclavicular recurrence and survival. In our
cohort study, we found that pathological T stage was signiﬁcantly
associated with regional recurrence. The 5-year RRFR for Stage
≥pT2 was 94.7%, which was lower than the pT1 stage (100.0%).
Other factors, such as lymphovascular invasion, the number of posi-
tive LNs, and the percentage of positive LNs were not signiﬁcantly
associated with RRFR, probably because there were very few events.
Because a small number of patients had regional recurrences, multi-
variate analyses could not be performed for these factors.
Standard tangential WBI can unintentionally irradiate some
of the axillary LNs. In our study, the average mean dose to axi-
llary Level 1 and the interpectoral LNs was 35.4 ± 6.7 Gy
(70.8% ± 13.4% of the prescribed dose) and 30.8 ± 10.2 Gy
(61.6% ± 20.4% of the prescribed dose), respectively. These results
indicate that patients did not receive sufﬁcient doses to axillary
Level 1 or the interpectoral LNs. Furthermore, the average mean
dose to Level 2 was lower; thus, standard WBI could not cover the
axillary LNs. Our results are consistent with those of Reed et al.
[11] and Rezink et al. [12].
The ACOSOG Z0011 trial demonstrated equivalent survival
with one to two positive sentinel lymph nodes who were randomly
assigned to the sentinel lymph node biopsy-alone group or the axil-
lary dissection group [19]. They also reported that axillary
recurrences were rare (0.9%) among the patients who did not
receive axillary dissection, despite the 27% incidence of additional
nodal disease among patients who were assigned to axillary dissec-
tion [20]. Therefore, incidental irradiation to the axillary LNs with
WBI is thought to play a role in reducing the regional recurrences.
However, the irradiation dose to the axillary LNs with WBI is insuf-
ﬁcient as a treatment dose, and the practical role of WBI in reducing
the regional recurrences is unclear. No studies have determined the
relationship between the dose to the axillary LNs and regional
recurrence in patients who are omitted axillary dissection versus
those who received axillary dissection. In our study, we classiﬁed
patients who received axillary dissection into two groups in accord-
ance with the percentage of positive LNs, and we investigated the
relationship between the dose to the axillary LNs and the RRFR.
Neither the dose to Level 1 nor the dose to the interpectoral LNs
was related to the RRFR. A possible reason is that most patients
received enough axillary dissection even if the percentage of positive
LNs was >20%. Truong et al. [14] reported that after mastectomy,
involvement of ≥20% of the LNs was associated with locoregional
failure; a few years earlier, those authors had found that >25% posi-
tive LNs was an adverse prognostic factor for locoregional recur-
rence when no radiotherapy was performed [21]. However, Fortin
et al. [9] divided patients with one to three positive LNs into
groups with <40% versus ≥40% positive LNs to investigate regional
failure. In our cohort, only one patient had >40% positive LNs.
Most patients may have received enough axillary dissection so that
irradiation to the axillary LNs was unnecessary. When there is insuf-
ﬁcient axillary dissection or when axillary dissection with positive
sentinel LNs is omitted, an increased radiation dose to the axillary
LNs may reduce regional recurrence. Further studies will be needed
to resolve this issue.
Because of its retrospective design, our study may have some
limitations, such as missing data for some parameters of
lymphovascular invasion, nuclear grade, and hormonal receptors, as
well as the absence of information for extracapsular invasion and
the level of involved axillary LNs. Moreover, the parameters that
determine the subtype and affect prognosis, such as the human epi-
dermal growth factor receptor-2 status and Ki67 labeling index,
were absent. Our chemotherapy regimen was very diverse and dif-
fered from recent standard regimens used in this type of cohort.
One-third of the patients who received chemotherapy were treated
using a single agent (such as oral ﬂuorouracil) that is no longer a
standard chemotherapeutic treatment for pathological N1 cancer. A
prospective analysis will be needed to resolve these limitations.
In conclusion, while the pathological T stage was the prognostic
factor best associated with regional recurrence, very few regional
recurrences were observed in early breast cancer patients with one
to three positive LNs treated with BCS followed by WBI.
Unintentional radiation doses to axillary Level 1 and the interpec-
toral LNs using the tangential ﬁeld of WBI were not associated with
regional LN recurrence after axillary dissection.
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